Sorafenib Soranib 200mg - Anticancer drugs | Cipla | MHP

                                         SORANIB

DESCRIPTION

                   Sorafenib sold under the brand name Soranib 200mg. Soranib 200mg Tablets belongs to the group of tyrosine kinase inhibitor or inhibitor of angiogensis. The drug is a type of targeted therapy Soranib 200mg is a prescription drug used under the supervision of health care provider.

INDICATION

              Soranib 200mg Tablets is a anticancer drug and indicated for the treatment of some condition as Advanced renal cell carcinoma Hepatocellular carcinoma Metastatic thyroid carcinoma

Soranib 200mg

                 

                                            DOSAGE

IN RENAL CELL CARCINOMA

            The dose of Soranib 200mg is given as 400mg should be taken orally as twice daily for at least one hour before or two hours after the meal

THYROID CARCINOMA

            The dose of Soranib 200mg Tablets is given as 400mg should be taken orally as twice daily for at least one hour before or two hours after the meal

HEPATOCELLULAR CARCINOMA

             The usual dose of Soranib 200mg is given as 400mg should be taken orally as twice daily for at least one hour before or two hours after the meal.

SORAFENAT WORKS IN THE BODY

              Soranib 200mg Tablets includes in deficiency of tumor cell multiplication Soranib 200mg interfere with multiple intracellular and cell surface kinase These enzymes are specific for tumor cell signaling, angiogenesis and apoptosis. Soranib 200mg causes to reduce the blood flow to the cancer cells By prohibiting these enzymes (kinase), genetic transcription includes in cell proliferation and angiogenesis is blocked.

DRUG INTERACTION

             Interaction of Soranib 200mg Tablets with Rifampin a strong CYP3A4 inducer, administered at a dose of 600mg single use for 5 days with Soranib causes decrease AUC of Sorafenib 200mg Interaction with neomycin will reduce the AUC of Sorafenib 200mg Tablets Interaction with acetaminophen will raises the hepatoxicity effect of Sorafenib 200mg Interaction with Bevacizumab will increase the toxic effect of Sorafenib.

PRODUCTS DETAILS

        Brand : Soranib
        Ingredients : Sorafenib
        Strength : 200mg
        Manufactured : Cipla
        Package : 120 Tablets

BODY WORKS FOR THE DRUG SORAFENIB

ABSORPTION

         The Soranib 200mg Tablets bioavailability is 38 to 49% The time to peak serum concentration in 3 hours. High fat meals may decrease the bioavailability of Sorafenib 200mg

DISTRIBUTION

         The drug Soranib 200mg tablets has Human plasma protein bound is 99.5%

METABOLISM

          In liver Soranib 200mg is highly metabolized, it go through oxidative metabolism with the help of CYP3A4 and Glucuronidation by UGT1A9 The main flowing metabolite in serum is pyridine N oxide

ELIMINATION

        The dose excreted via feces 77% The dose excreted via urine 19% as glucuronidated metabolites Soranib 200mg tablets half life is 25 to 48 hours

SAFETY PRECAUTIONS &

CONTRAINDICATION

            Soranib 200mg should not be used, in case of lung cancer, being treated with platinum containing chemo drugs and taxol drugs Soranib 200mg Tablets able to cause heart problems, stop the medicine in case of dizziness, fainting, sweating or shortening of breath Soranib 200mg causes severe bleeding; care should be taken while getting Soranib 200mg Tablets Stop the Tablet Soranib 200mg in case of;

blood in urine or stools, blood while coughing, Vaginal bleeding Hemorrhage risk QT prolongation. High occurrence of skin toxicity and rashes. Impairs exogenous thyroid suppression. Hypersentivity to the drug and any product of expicients.

SIDE EFFECT

              Lymphopenia Neutropenia Hemorrhage Hypertension Neuropathy Anorexia Headache Joint pain Congestive heart failure Acute renal failure Angiodema arrhythmia Interstitial lung disease Post marketing reports: Hypersensitivity reactions: angioedema, anaphylactic reaction Hepatobiliary disorders: hepatitis, hepatic failure and death Musculoskeletal: rhabdomyolysis, osteonecrosis of the jaw Pulmonary: interstitial lung disease

PREGNANCY

          Category D: Soranib 200mg tablets can harm to an fetus and cause injury and even death to the unborn baby if you treatment during the 2nd and 3rd trimesters of pregnancy, pregnant women do not use the Soranib medicine without the knowledge of your doctor.

LACTATION

           The medicine passes into breast milk is not known or could harm a new born baby. Do not use Soranib 200mg medication, if your breast feeding.

STORAGE

          Soranib 200mg tablets should be store at 25°C (77°F); excursion are allowed between 15°C and 30oC (59°F and 86°F) Protect from moisture, heat and light

MISSED DOSE

           If patient missed to take Soranib 200mg tablet, they may get advice from medical practitioner (consult) for administration of the missed dose within the time Or the missed dose should be skipped and follow the next dosing schedule Do not have double the dose.

CONTACT DETAILS

Email : millionhealthpharmaceuticals@gmail.com
Phone Number : +91-9940472902
Website : https://millionpharma.com/soranib.php